Furthermore, the therapeutic benefit of CXCR4 modulation in cancer is extensively demonstrated in the literature, using both neutralising antibodies and siRNA-mediated knockdown of the receptor in preclinical metastatic tumour models[34-37]. The gene discussed is CXCR4; the disease is cancer.